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Humans have evolved along with the millions of microorganisms that populate their
bodies. Thesemicrobes (1014) outnumber human cells by 10 to 1 and account for 3×106
genes, more than ten times the 25,000 human genes. This microbial metagenome acts
as our “other genome” and like our own genes, is unique to the individual. Recent
international efforts such as the Human Microbiome Project (HMP) and the MetaHIT
Project have helped catalog these microbial genomes using culture-independent,
high-throughput, next-generation sequencing. This manuscript will describe recent
efforts to define microbial diversity in the female reproductive tract because of the impact
that microbial function has on reproductive efficiency. In this review, we will discuss
current evidence that microbial communities are critical for maintaining reproductive
health and how perturbations of microbial community structures can impact reproductive
health from the aspect of infection, reproductive cyclicity, pregnancy, and disease states.
Investigations of the human microbiome are propelling interventional strategies from
treating medical populations to treating individual patients. In particular, we highlight
how understanding and defining microbial community structures in different disease and
physiological states have lead to the discovery of biomarkers and, more importantly,
the development and implementation of microbial intervention strategies (probiotics)
into modern day medicine. Finally this review will conclude with a literature summary
of the effectiveness of microbial intervention strategies that have been implemented in
animal and human models of disease and the potential for integrating these microbial
intervention strategies into standard clinical practice.
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Understanding the Human Microbiome
As humans evolved, so did the millions of microorganisms that populate the human body. These
microbes (1014) outnumber human cells 10 to one and account for 3 × 106 genes, more than 10
times the 25,000 genes comprising the human genome. This microbial metagenome acts as an
“extended human genome,” and, like our own genes, is highly specific to the individual. Recent
international efforts such as the Human Microbiome Project (HMP) and the MetaHIT Project
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have helped catalog these microbial genomes using culture-
independent, high-throughput, next-generation sequencing (Cai
et al., 2010; Human Microbiome Jumpstart Reference Strains
Consortium et al., 2010; Lozupone et al., 2012; Human Micro-
biome Project Consortium, 2012a,b). They have shown that, out
of 55 bacterial divisions, the metagenome is dominated by only
a few bacterial phyla (Firmicutes, Bacteriodetes, Actinobacte-
ria, and Proteobacteria) (Ley et al., 2007). The microbiome per-
forms both digestive and metabolic functions, and is responsi-
ble for 40% of the host’s energy intake (Round and Mazmanian,
2009). Another important role for the microbiome is develop-
ment of the host’s immune system, as mice lacking gut microbes
are defective in immune cell maturation and response (Round
and Mazmanian, 2009; Chung et al., 2012). Importantly, per-
turbations in the microbiome can lead to both metabolic and
immune diseases, highlighting the importance of understanding
the “healthy” human microbiome and its interaction with the
host. Symbiosis between host and the gut microbiome plays an
important role in maintaining a physiological homeostasis. Sup-
porting this, an individual’s microbiome phylotype is specific and
stable, suggesting that each host has a unique relationship with
its microbiome (Costello et al., 2009). In other words, there is
an individualized core microbiome responsible for maintaining
a healthy state, and any significant deviation from that core may
affect an individual’s risk for disease (Sartor, 2004; Ley et al., 2006;
Manichanh et al., 2008).
Historically, identification of individual microbes has been
difficult because of the inability to culture many bacteria
in vitro. With the genomic era came the development of
culture-independent technologies (genome sequencing) that
TABLE 1 | Summary of literature on microbial dynamics and reproductive physiology.
Reproductive State/disorder Effect on microbiome References
Menstruation Altered vaginal microbiome stability, but no change in microbial
function
Gajer et al., 2012
Placental function Modulation of placental function and metabolism Aagaard et al., 2014
Preterm birth (PTB) Altered microbial diversity, but not richness;
Associated with Lactobacillus iners
Brocklehurst et al., 2013
Barbonetti et al., 2011
Pregnancy Reduction in microbial richness and diversity;
Induced microbial stability
Dechen et al., 2010
Barbonetti et al., 2011; Aagaard et al., 2012
Vaginal parturition Colonization of fetal microbiome Dominguez et al., 2003; Huurre et al., 2008; Groeger et al.,
2013; Tojo et al., 2014
Bacterial vaginosis (BV) Altered vaginal bacterial colonization; Associated with PTB, STDs,
and UTIs
Roger et al., 2010; Aaltonen et al., 2011; Brotman, 2011
Pelvic inflammatory disease (PID) Ascension of pathogens from the lower to upper reproductive
tract; Pathogens connected to PID also associated with BV
van Oostrum et al., 2013
STDs/STIs Associated with BV;
Decreased vaginal microbiome-vaginal cavity immune system
relationship
Roger et al., 2010; Jaiyeoba et al., 2011; Taylor et al., 2013
Klebanoff and Coombs, 1991; Hill and Anderson, 1992;
Brotman et al., 2007, 2010; Mirmonsef et al., 2011
Cancers of the reproductive tract Shift from protective to harmful bacteria;
Associated with viral infections (HIV, HPV);
Link between BV and precancerous lesions/malignancy
progression of cervical cancer
Nicol et al., 2005
Martin et al., 1999; Brotman et al., 2010
Barrington et al., 1997; Parkin, 2006; Denslow et al., 2011
Ovarian stimulation for IVF Altered vaginal microbiome, but no change in diversity of microbial
species
Hyman et al., 2013
Estrogen circulation Estrabolome metabolizing functions Cole et al., 1985; Gadelle et al., 1985; Dabek et al., 2008;
Hou et al., 2013; Mandar, 2013
allowed for genomic sequencing of 16S ribosomal genes that
accurately identified and allowed for classification of millions of
bacterial species (Tringe et al., 2005; Mardis, 2008).
The precepts of the HMP provide a foundation and model
for advancing the tools, approaches, databases and fundamen-
tal contributions of microbiome research to health and disease
far beyond Koch’s Postulates into the realm of individualized
medicine. The application of these approaches, and the resulting
concepts, span far beyond the microbiomes of sympatric micro-
bial relationships found in humans to those in food animals,
non-human primates and free living communities. Our under-
standing of the human microbiome has altered the future land-
scape of our approach to health and disease. We now consider
the individual as a superorganism, combining our unique human
genome with the microbiome, including an assessment of micro-
bial population structure with an assessment of how the micro-
bial community functions. In light of this new genomic revolu-
tion, we will review the microbiomes of the female reproductive
tract, focusing on the role of the vaginal and placental micro-
biomes, diseases that result from disruption of thesemicrobiomes
and therapies based on manipulation of these microbiomes
(Table 1).
Reproductive Tract Microbiomes
Anatomical Features of the Reproductive System
for Pathogen Resistance
The female reproductive tract is composed of (anterior to pos-
terior): the ovaries, fallopian tubes, uterus, cervix, and vagina.
The anterior structures of the reproductive system represent a
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bacterial naive environment that ensures efficient gamete pro-
duction and transport, fertilization of the ovum, embryonic
development and implantation due to the absence of inflamma-
tory immune responses. As the outer orifice to the reproductive
tract, the vagina serves as the first line of defense to protect
against entry of harmful bacteria and other pathogens into the
immunologically privileged sites of the uterus and fallopian
tubes. The microbial communities of the vagina serve as the
“guard dogs,” along with the acidic pH, to regulate microbial
growth and transmission. Anterior to the vagina lies the cervix,
which serves as a physical barrier for pathogen entry to the uterus
and fallopian tubes. Both the vagina and cervix work together,
albeit through different mechanisms, to protect and maintain
reproductive health. The cervical rings or folds create an obsta-
cle course for both pathogens and sperm cells alike to traverse,
while the hormonally regulated secretions of the cervix can cre-
ate either a viscous (post-ovulation) or watery (pre-ovulatory)
lubrication for flushing microorganisms out of the vagina during
copulation (Yarbrough et al., 2014). Infections of the upper repro-
ductive tract occur when microbial communities of the vagina
are altered to permit the overgrowth of harmful microorganisms
that then overwhelm the cervical barrier and breach the immune
protection and negatively impact the commensal bacteria of the
upper reproductive system. This breach results in the pathogen-
esis of reproductive disorders including preterm birth (PTB),
pelvic inflammation, sexual transmitted diseases, gynecological
cancers and other diseases. Understanding and more impor-
tantly, maintaining a healthy vaginal microbial environment is
critical to preventing many reproductive disorders associated
with many pathogens.
The Vaginal Microbiome
The human vaginal microbiome undergoes continuous evo-
lution as the host encounters and responds to a number of
environmental and physiological disruptions. Application of
genomic technologies (mentioned above) to the vaginal ecosys-
tem has identified five distinctive microbial communities, the
specific proportions of which are significantly shaped by a
woman’s race/ethnicity (Ravel et al., 2011) and personal hygiene
habits (Ness et al., 2002). Lactobacillus is the dominant fam-
ily of bacterial species (L. crispatus, L. iners, L. gasseri, and L.
jensenii) comprising four out of the five major vaginal micro-
bial communities, with the final microbial community com-
posed of a variety of strict and facultative anaerobes (Ravel
et al., 2011). In addition, identification of species composi-
tion is valuable but more important is the functionality of
microbial species within these unique communities. Lactobacil-
lus species function to protect the reproductive tract utilizing
several mechanisms, primarily through production of lactic acid,
which lowers the pH of the vaginal environment, and through
activation innate immune responses (Kim et al., 2006; Fichorova
et al., 2011). Mechanisms employed by non-lactobacillus-
dominant communities to regulate the vaginal ecosystem are
relatively unexplored but would greatly enhance the under-
standing of how a “healthy” vaginal environment is maintained
in the presence of diverse environmental and physiological
agitations.
Hormonal Regulation
Reproductive cyclicity is defined as repeated opportunities for
conception, implantation and pregnancy. Cyclicity is regulated
by ovarian hormones and involves dynamic changes in the ovary
and also endometrial remodeling. Menstruation is a physiologi-
cal event that initiates uterine endometrial remodeling required
for pregnancy in humans and some non-human primates. The
fall of ovarian hormones estrogen and progesterone triggersmen-
struation but is also associated with changes in vaginal microbial
communities. Very few studies have investigated the regulation
of microbial communities by ovarian hormones (Hickey et al.,
2013) and only one study has reported changes in microbial com-
munity stability throughout the menstrual cycle (Gajer et al.,
2012). The Gajer study looked at the vaginal microbiome stabil-
ity over a period of 16 weeks in 32 reproductive aged women.
This study concluded that the Jensen-Shannon divergence rate of
change (i.e., a measure of the bacterial deviation from constancy)
was lowest when estradiol levels were the highest, indicating an
inverse relationship between constancy and estradiol levels. The
greatest divergence rate of change was found at the onset of men-
struation, gradually declined as estradiol levels rose and then
quickly rose during the late secretory stage (decline of estradiol
levels) of themenstrual cycle. Although the authors found greater
community stability under estrogen dominance this did not coin-
cide with an increase of community diversity. Additionally, the
change in community stability did not lead to fluctuations in
microbial function (maintenance of vaginal pH and lactic acid
production), indicating that there can be redundant functions
in microbial species within a community. Individuals who have
lost this redundancy may be those more susceptible to reproduc-
tive disorders associated with infertility and reproductive disease
states.
Placental and Amniotic Fluid Microbiomes
For several decades we have known that bacteria are found in
what is considered to be “sterile” environments such as the uterus
and fetal tissues (Harris and Brown, 1927). More recent investi-
gations have supported this original observation that the placenta
and amniotic fluid (AF) surrounding the fetus during pregnancy
are not “sterile” environments and that the presence of bacte-
rial species has an impact on gestation and parturition (Satokari
et al., 2009; Fardini et al., 2010; DiGiulio, 2012; Mendz et al.,
2013; Aagaard et al., 2014; Doyle et al., 2014). A recent review
of investigations that characterized bacteria found in the AF has
elucidated that while the presence of bacteria in AF is associ-
ated with adverse obstetrical outcomes, bacteria are still present
in the AF of women with “healthy” term pregnancies (Payne and
Bayatibojakhi, 2014). Interestingly, it has been reported that the
placenta contains similar bacterial species to that found in the
oral cavity (Douvier et al., 1999). However, this study was lim-
ited as it utilized only placental tissue from patients with known
chorioamnionitis (infection of the chorion and amnion layer of
the placenta) and also relied on culture based detection meth-
ods to identify bacterial species. With the emergence of power-
ful DNA sequencing techniques, it has now been reported that
even non-infectious “healthy” placental tissue harbors a num-
ber of microbial species establishing that placental tissue has a
Frontiers in Physiology | www.frontiersin.org 3 April 2015 | Volume 6 | Article 97
Braundmeier et al. Microbiome of the reproductive tract
microbial signature similar to the oral cavity (Satokari et al.,
2009; Aagaard et al., 2014; Antony et al., 2014; Doyle et al.,
2014). Hence transmission of bacterial species from the oral cav-
ity to the AF and placenta can be benign or result in adverse
pregnancy outcomes (Hill, 1998; Han et al., 2004, 2006, 2009)
(to be discussed later). In addition, transmission of certain bac-
terial species, Streptococcus, Escherichia coli, Shigells, Proteus,
Enterobactera and Candida from the gastrointestinal (GI) tract
to reproductive tissues (vagina, endometrium, and placenta) also
negatively impact pregnancy (Dechen et al., 2010) but have been
shown to have important roles in amino acid metabolism and
positively impact sperm transport and fertility (Barbonetti et al.,
2011). Similarly, there are immunologically beneficial bacterial
species from the gastrointestinal (GI) tract to the placenta, specif-
ically bifidobacteria or lactobacilli, have been shown to benefit
fetal development through early programming of the naïve fetal
immune system and protection of the fetus from activated mater-
nal immune cells (Satokari et al., 2009). Hence the transmission
of bacterial species from other mucosal tissues to the placenta
and amniotic fluid throughout gestation has both symbiotic and
pathogenic outcomes.




Pregnancy is considered a “healthy” parasite-host physiological
state, which is supported by elevated levels of both estrogen and
progesterone. The presence of a growing fetus (parasite), elevated
ovarian hormone levels and placental factors induces dynamic
changes in the mother’s (host) microbial communities. Recently,
a comprehensive study investigating microbial shifts throughout
pregnancy reported that as early as 18–24 gestational weeks there
was alteration of microbial richness in the vaginal microbiome
(Aagaard et al., 2012). This study also reported that while gesta-
tional timing and vaginal location were important in determin-
ing microbial community structure that overall throughout the
entire pregnancy there were reductions in both microbial rich-
ness and diversity throughout all stages of pregnancy when com-
pared to non-pregnant women (Aagaard et al., 2012). Further,
investigation on the influence of pregnancy on specific bacterial
taxonomy expression, showed that pregnancy was highly associ-
ated with the expression of Lactobacillus, Bifidobacteriaceae and
Streptococcaceae operational taxonomic units. More recent data
has confirmed that pregnancy induces microbial stability within
the vaginal cavity dominated by Lactobacillus species (Petricevic
et al., 2014; Walther-Antonio et al., 2014). Enhanced expression
of members within these particular bacterial families may func-
tion to improve immune system function (Groeger et al., 2013)
for protection of the fetus from the maternal immune response
and to protect the uterine environment from pathogen invasion
(Fichorova et al., 2011).
The placenta is a unique organ in that it is only present dur-
ing pregnancy but is vital for the transfer of nutrients and other
factors from maternal to fetal circulation to support fetal devel-
opment. Thus it is not surprising that bacterial species that colo-
nize the placental tissues have a unique metabolic capacity unlike
that of other mucosal tissues. Using a metagenomic approach,
Aagaard et al, was able to identify the metabolic profile of bac-
terial taxonomy found within the placenta (Aagaard et al., 2014).
This study reported that the placenta had a higher abundance of
bacterial gene profiles supporting metabolism of cofactors and
vitamins than other observed tissues (stool, tongue, posterior
vagina, etc.). They also observed a decreased abundance of bacte-
rial gene profiles associated with carbohydrate and amino acid
metabolism. Accordingly the relative abundance of metabolic
pathways was influenced by both gestational age and also history
of previous maternal infections. Collectively this study demon-
strated that the bacteria colonizing placental tissues modulates
overall placental function and may be indicative of placental and
maternal health.
Fetal Inoculation
As introduced earlier in this review, there is evidence that sup-
ports the benefit of bacterial transmission from the mother to the
fetus during gestation. One major advantage of maternal trans-
mission of bacterial strains to the fetus is to populate “naïve”
fetal tissues, such as the gastrointestinal and immune systems,
with beneficial bacteria that would aid fetal metabolism and con-
fer immune protection upon birth. Although it has been highly
reported that transmission of positive bacterial strains occurs
during the descent of the fetus through the vaginal canal (as
discussed below) there is also transmission of bacterial strains
through placental hematogenous transmission (Fardini et al.,
2010). Transmission of commensal intestinal bacteria, mainly
Bifidobacterium and Lactobacillus rhamnosus, was found to be
present in the majority of placental tissues examined, regardless
of mode of delivery (Satokari et al., 2009). The identification of
these particular bacterial species is highly significant because of
the importance of these strains in modulating immune health
(reviewed in Tojo et al., 2014).
Evidence suggests an additional role for the mother’s vaginal
microbial community, in colonizing the fetal microbiome during
parturition. Fetal descent into the vaginal canal during parturi-
tion creates an intimate contact between fetal orifices (oral and
rectal) and the maternal vaginal microbial communities. The the-
ory of maternal colonization of the fetal microbiome has been
validated through investigations comparing infant microbiome
signatures of different delivery methods (Dominguez et al., 2003;
Huurre et al., 2008) and gestational age at delivery (Vassallo and
Walker, 2008; Fanca-Berthon et al., 2010). These studies found
that infants born via vaginal delivery had “healthy” postnatal
microbial communities similar to their mother’s microbial com-
munities. An example of postnatal inoculation is the increased
levels of Bifidobacterium and Lactobacillus species found in fetal
stool samples collected at different timepoints after birth (Makino
et al., 2013), indicating further enrichment of the fetal GI micro-
biome from that which occurred in utero. Furthermore, infants
born via vaginal delivery that were breastfed had gut microbiome
profiles that favored greater immunological protection compared
with children born via cesarean section (Gronlund et al., 2007;
Roger et al., 2010; Aaltonen et al., 2011; Decker et al., 2011;
Cabrera-Rubio et al., 2012; Guarino et al., 2012). Promoting these
additional positive effects of vaginal delivery and breastfeeding
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maymold future practices for obstetrical care in the United States
to reduce the rate of elective cesarean sections.
Pathogenic Relationships
Bacterial Vaginosis
Microbial community composition and richness is always sub-
jected to a state of “normal” fluctuation. When the degree of fluc-
tuation becomes too severe, the microbial relationships of these
communities shift from symbiotic to pathogenic (disease). Bacte-
rial Vaginosis is the condition of abnormal bacterial colonization
of the vaginal cavity and has been associated with other patho-
logical conditions such as infertility, PTB, sexual transmitted dis-
eases, and urinary tract infections, among others (Quan, 2010;
Brotman, 2011; Dielubanza and Schaeffer, 2011). Investigation
into metabolic markers of BV has linked different disease symp-
toms (odor, epithelial integrity, discharge) with specific bacterial
species (Yeoman et al., 2013). Utilization of 16S rDNA sequenc-
ing technology indicated that bacterial community richness and
diversity of strictly anaerobic bacteria was increased in women
with BV (Fredricks et al., 2005; Yeoman et al., 2013). However
the same anaerobic species (Gardnerella, Atopobium, Mobilun-
cus and Prevotella) found in women with symptomatic BV are
also similar to a bacterial community state found in women with
asymptomatic healthy women (Ravel et al., 2011; Yeoman et al.,
2013). The diversity of the vaginal microbiome among each indi-
vidual complicates the ability to determine a bacterial “signa-
ture” of BV from that of the temporal changes in the vaginal
microbiome due to reproductive cyclicity, personal hygiene or
other numerous variables. This temporal fluctuation of the vagi-
nal microbiomemakes it difficult to identify bacterial species that
are causative for BV or the invasion of opportunistic bacterial
species that colonize and populate the vaginal microbiome dur-
ing environmental changes of the vaginal cavity. The difficulty in
identification of a causative pathogen for BV also increases the
difficulty of developing effective treatments for BV.
Treatment protocols for BV include antibiotic therapy either
with oral tablets or vaginal creams (Centers for Disease Con-
trol and Prevention et al., 2006). Additionally, the utilization
of combo or progestin only oral contraception drugs (OCPs)
has shown a protective effect to development of BV through
hormonal stabilization of microbial communities in the vagi-
nal canal (Rifkin et al., 2009). However, reoccurrence of dis-
ease within 1 year following the cessation of treatment is high
(Bradshaw et al., 2006). The current medical challenges associ-
ated with treating BV are: (1) diagnosis in patients (especially
those who are asymptomatic) (Ma et al., 2012; Drell et al., 2013),
(2) treatment of disease (anti-microbial vs. probiotics) (reviewed
in Donders, 2010; Brocklehurst et al., 2013) and (3) etiology of
disease (fulfilling Koch’s postulates of disease) (Fredericks and
Relman, 1996). Thus, even centuries since its discovery, BV still
remains a nuisance for clinicians worldwide and a precursor for
the development of other health conditions.
Gynecological and Obstetrical Complications
Pregnancy-associated vaginal microbiome profiles can be uti-
lized as screening tools to assess obstetrical and perinatal com-
plications prior to symptomatic presentation. Multiple studies
have investigated the correlation between PTB and the diversity
and richness of the microbial communities within the vaginal
canal. Using a culture- independent approach and chain termina-
tor sequencing technology to analyze the vaginal microbiome of
patients at risk for a subsequent pre-term birth, the authors found
that both Caucasian and African American women with PTB had
altered microbial diversity but not richness compared with the
term gestational counterparts (Hyman et al., 2013). Investiga-
tions on the diversity of Lactobacillus species during pregnancy
indicated that expression of Lactobacillus iners was highly associ-
ated with PTB (Petricevic et al., 2014). Additionally, it has been
shown that women with bacterial vaginosis (BV), an abnormal
bacterial colonization of the vaginal cavity, are at an increased
risk for PTB, early pregnancy loss (van Oostrum et al., 2013) and
failure of IVF therapy (Hyman et al., 2012). These data suggest
that using more advanced “next-generation” sequencing to pro-
file pregnancy-associated vaginal microbiome may help identify
patients at high risk for PTB.
Pelvic Inflammatory Disease and Sexual Transmitted
Diseases/Infections
Pelvic inflammatory disease (PID) is defined as infection and
inflammation of the female genital tract. The pathobiology of this
disease is due to the ascension of pathogens from the lower to
the upper reproductive tract which can result in serious and long
term negative implications for reproductive function (infertil-
ity, salpingectomy and/or hysterectomy). Many of the pathogens
implicated in the etiology of PID are associated with BV (Taylor
et al., 2013) but to date there is a lack of substantial evidence that
demonstrates a causal relationship between particular organisms
and the development of PID. Further evaluation of the micro-
biota in women with PID could elucidate specific organisms that
can be utilized as a screening tool to identify women at risk for
PID prior to onset of clinical systems. The current recommen-
dations for treatment of PID are containment of pathogens in
the genital tract and utilization of broad-spectrum antibiotics
that adequately cover the associated species of microorganisms
(Jaiyeoba et al., 2011).
Sexual transmitted disease (STD) and sexually transmitted
infection (STI) acquisition are additional health concerns that are
affiliated with commonmicroorganisms, similar to BV (Brotman,
2011). Woman with reoccurring BV are also at a significantly ele-
vated risk for many types of STD’s or STI’s including HIV (Kaul
et al., 2008), gonococcal, chlamydial and trichomonal infections
(Brotman et al., 2010). The association of BV occurrence with
contraction of other STD’s and STI’s is due to a variety of factors.
Patients with a high recurrence of BV are likely to also be infected
with STDs due to sexual behavioral choices that can influence
the vaginal microbiome such as participation in oral sex and
lack of physical contraceptive utilization (Brotman et al., 2007).
Additionally, the correlation between BV and STD/STI’s may be
reflective of the relationship between the vaginal microbiome and
the host immunity of the vaginal cavity. Immune protection of
the vaginal cavity is created by certain microorganisms (mainly
lactobacillus genus) that: (1) neutralize and prohibit the coloniza-
tion of harmful pathogens (bacterial and viral) and (2) activate
the innate immunity of the lower genital tract (Mirmonsef et al.,
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2011). Lactobacilli production of high levels of hydrogen perox-
ide (H2O2) are toxic to HIV viral replication and inhibit CD4+ T
cell activation therefore, decreasing HIV transmission (Klebanoff
and Coombs, 1991; Hill and Anderson, 1992). Although commu-
nication betweenmicrobial communities and the immune system
can be beneficial for protecting common pathogen entry niches, a
disruption of the vaginal cavity’s immune system could potentiate
the development of reproductive diseases/infections and increase
the severity of infection (Martin et al., 1999; Sha et al., 2005)
which can predispose the vaginal mucosal membrane for the
development of certain types of cancer (reviewed in Nicol et al.,
2005).
Cancers of the Reproductive Tract
A disruption of the vaginal microbial communities can lead to
decreased immune protection, thereby increasing susceptibility
of the epithelial lining of reproductive tissues to viral infections.
The shift of microbial communities from those that are protec-
tive (Lactobacillus genus) to those that are harmful anaerobic
bacteria (Gardenerella vaginalis, Atopobium vaginae, Mobilun-
cus and Prevotella species), as occurs with BV, can damage the
epithelial layer of reproductive tissues making it penetrable to
viral entry, especially those viruses that are sexually transmit-
ted (HIV and HPV) (Denslow et al., 2011; Mirmonsef et al.,
2011). Importantly, infection with HIV or HPV is attributed to
the development of several cancers including cervical cancer,
Kaposi sarcoma, Non-Hodgkin lymphoma, ano-genital cancer,
and cancers of the mouth and oropharynx (Parkin, 2006). Sim-
ilarly, several studies have shown a linkage between the occur-
rence of BV and the development of precancerous lesions and
malignancy progression in patients diagnosed with cervical can-
cer (Guijon et al., 1992; Platz-Christensen et al., 1994; Barrington
et al., 1997). Furthermore, a recent meta-analysis reported a clear
association between BV and cervical cancer (Gillet et al., 2012).
These studies provide support for the importance of maintaining
a “normal” vaginal ecosystem to avoid development of malignant
pathology.
Infertility and Assisted Reproductive Technology
Detailed research is lacking on the association between reproduc-
tive tract microbiomes (vaginal or uterine) and infertility rates or
the successfulness of Assisted Reproductive Technologies (ART).
It is known that inoculation of the uterine cavity with harmful
bacteria by the embryo transfer catheter adversely effects posi-
tive pregnancy outcome (Egbase et al., 1996, 1999; Fanchin et al.,
1998). Additionally, women with STD’s or high reoccurring rates
of BV also have an increased incidence of failed in vitro fertil-
ization (IVF) embryo transfer (ET) attempts (Witkin et al., 1995;
Liversedge et al., 1999). In contrast, while intercourse among het-
erosexual partners may influence the urogenital microbiomes of
each individual the penile microbiome has not been shown to be
associated with fertility status in males (Hou et al., 2013; Man-
dar, 2013). Together these data suggest that successful embry-
onic implantation can be impeded by the presence of potentially
pathogenic bacterial species.
It is well documented that the vaginal microbiome is highly
influenced by the secretion patterns of ovarian hormones (Ravel
et al., 2011). Recently, the composition and diversity of the
vaginal microbiome was analyzed in patients undergoing dif-
ferent ovarian stimulation protocols for IVF and correlated to
clinical outcome (Hyman et al., 2012). The authors reported that
ovarian stimulation did result in alterations of the vaginal micro-
biome but the diversity of the microbial species was not different
among the different protocols tested. Importantly, microbiome
composition at the time of embryo transfer was found to cor-
relate with a successful IVF outcome as, patients for whom IVF
resulted in a live birth had significant differences in their vagi-
nal microbiomes compared to women who were unsuccessful
at achieving pregnancy. Determining the mechanism by which
the vaginal microbiome may influence ART outcomes would be
highly beneficial for guiding clinical recommendations on which
ART should be implemented, if any, to patients seeking infertility
treatment.
Estrabolome
While the microbial community profiles of reproductive tissues
are distinct from those reported in the gastrointestinal (GI) tract,
it is important to mention that the function of reproductive
organs is highly regulated by the estrogen metabolizing func-
tions of bacterial species contained within the GI. It has long
been known that bacterial species found in the GI tract possess
enzymatic activity, which is essential for processing estrogens to
be released back into circulation or conjugation of estrogens to
be excreted through urine or fecal production (Cole et al., 1985;
Gadelle et al., 1985; Dabek et al., 2008). This process is known as
enterohepatic circulation (Adlercreutz et al., 1979) and the bacte-
rial species regulating this process are collectively known as the
estrabolome (reviewed in Plottel and Blaser, 2011). Alteration
of the estrabolome can result in either increased or decreased
peripheral circulating levels of estrogens, which can affect mul-
tiple reproductive functions including (ovarian and endometrial
cyclicity, pregnancy, infertility (Obst and Seamark, 1975; Gautray
et al., 1981; Filicori et al., 1991), infection (Luthje et al., 2014)
and malignancy (Kabat et al., 1997; Gupta et al., 1998). This indi-
cates the complexity of the regulation of physiological systems by
microbial communities in different regions of the human body
and stresses the importance of maintaining an overall “healthy”
microbiome to achieve overall health.
Individualized Medicine and the Human
Microbiome
Therapeutics
Microbiome-associated diseases are considered preventable or
treatable in the individualized medicine paradigm. Potential
means to maintain or restore the healthy state of a microbiome
include use of probiotics or prebiotics, implementing a change
in diet and use of unique gut- or reproductive-tract derived com-
mensals as treatment options to generate a balancedmicrobiome.
Mucosal surfaces, such as those of the reproductive and digestive
tract, are important portals of entry for diverse environmental
agents. Physical mucosal barriers and the mucosal immune sys-
tem play critical defensive roles by limiting tissue damage from
harmful exposures to foreign substances, including bacteria and
antigens (reviewed in Kaushic, 2009). Mucosal interfaces are, not
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surprisingly, rich with immune cells and are highly regulated to
maintain a balance between absorption of beneficial nutrients
and protection against harmful organisms and antigen (Brad-
shaw et al., 2006; Hickey et al., 2011). Perturbations of this system
are implicated in several common and chronic diseases, including
inflammatory bowel disease (reactions to commensal organisms),
celiac disease and food allergies (reaction to gluten and specific
foods), Helicobacter related gastritis (peptic ulcer disease, gas-
tric cancers related toHelicobacter), allergic disorders (associated
with reaction to foods), aero-antigens, and fungi. If the mucosal
environment represents a risk for contraction of local and dis-
tant disease, it also follows that it might serve as a target site
for reducing risk through focused efforts to prevent or reverse
harmful exposures. There is emerging interest in considering the
beneficial effects of commensal organisms, probiotics, and pre-
biotics, fecal transplants and mucosal immune system vaccina-
tion strategies. However for this to be successful, we need to
ascertain whether the compositional changes in the microbiome
are consequences or driving forces of the different diseases, and
finally, if different types of microbial therapeutics (individualized
medicine) can alter the development of different diseases.
Probiotics
Probiotic therapy describes the ingestion of living organisms, or
“good bacteria.” It is thought that probiotic therapy enhances
nutrient uptake and immune health, and that this could allevi-
ate reproductive disorders and reduce the occurrence of prema-
ture birth. While no direct evidence exists linking probiotic use
with a reduction of reproductive complications, there is an abun-
dance of evidence supporting probiotic utilization for improve-
ment of immune, gut barrier, placental, and cardiovascular func-
tions (reviewed in Reid et al., 2013). Dietary supplementation
with certain probiotic formulations has shown to reduce inflam-
matory responses in pregnant women by counteracting the shift
in microbial populations that can be inflammatory during late
pregnancy (Vitali et al., 2012). These data suggest that although
modulation of the vaginal and gastrointestinal microbiomes may
not directly target the uterine microbiome, pregnancy outcome
may be positively impacted through probiotic use through overall
enhancement of maternal health.
Probiotic therapy plays a role in treatment of urogenital dis-
eases as well (reviewed in Reid et al., 2004). Probiotic supplemen-
tation has been shown in pilot studies to be an equally (or more)
effective, short term, treatment compared to standard clinical
antibiotic treatments in patients with vaginitis and BV (Donders
et al., 2010; Ling et al., 2013). Further analysis of one pilot study
that utilized probiotics in patients with BV revealed that probi-
otics do not eliminate harmful taxonomy, as did antibiotics, but
rather suppressed the overgrowth of bacterial strains associated
with BV thus possibly leading to its enhanced effectiveness (Ling
et al., 2013). Additionally, it has been reported that inoculation of
the uterine microbiome with Lactobacillus crispatus at the time
of embryo transfer can increase implantation rates and reduce
colonization of pathogenic microorganisms (Sirota et al., 2014).
To date there is limited evidence for the beneficial effects of pro-
biotic therapy, strain composition and dosage for treatment of
reproductive disorders. However, rather than allowing this fact to
discourage use of probiotics, the scientific community needs to
robustly explore probiotics as potential therapies for improving
reproductive health.
Biomarkers
Biomarkers are molecular entities with clinical utility in early
detection, classification, prognosis, predicting response to ther-
apy, and theranosis of a patient’s disease. Specific and sensi-
tive biomarkers can lead to optimal individualized management
strategies including active surveillance, expectant management,
and surgical or other interventions. They can also lead to new
therapeutic trajectories. Biomarkers can reduce over-treatment,
under-treatment and incorrect treatment. Understanding the
complexity of a microbiome-mediated disease, such as by dys-
biosis (microbial imbalance), is critical, as most of these diseases
are not determined or defined by a single or even a few changes
in the microbial community structure. Capturing the molecular
heterogeneity of microbiome-associated disease is the first and
necessary step for a successful diagnostics strategy. This, and sys-
tematic addition of effective targeted interventions to the treat-
ment options contribute toward the main goal of personalized
(genomic)medical diagnostics (point of care predictors), by iden-
tification of microbiome quantitative traits or QTLs that predict
the risk for a clinical condition.
To achieve the ideal of individualized medicine through
understanding the human microbiome, we must understand the
symbiotic relationship between humans and microbes by char-
acterizing the microbiome of several mucosal tissues. Adding
microbiome profiles to the repertoire of biomarkers for preven-
tion, early detection and diagnosis of primary infections, compli-
cations and other health care conditions is crucial. For example,
fecal-based microbiome and metabolite signatures could pro-
vide unique opportunities for radically changing the detection
of chronic inflammation through identification of modifiable
dietary risk factors, and through recognition of high-risk pop-
ulations within whom endoscopic efforts can be focused. These
biomarkers could be used to identify populations at risk for dis-
ease associated with inflammation as well as to monitor response
of diet, probiotic, antibiotic, or other preventive interventions.
Summary
It is evident based on the expansive literature available to date,
that an individual’s microbiome serves as more than just a bac-
terial presence that resides in our body’s natural orifices. These
microbial environments are composed of numerous communi-
ties that function to create a symbiotic host-microbe relation-
ship through regulation of the immune system and healthy tis-
sue physiology. Microbial community dynamics may fluctuate
in species diversity and richness but can maintain a “normal”
microbial community due to redundancy among specific strains.
However, too much fluctuation in any microbial community
leaves the host susceptible to not only bacterial over-colonization
but also to pathogen entry. In this event there can be serious
damage to cellular layers and tissues of a physiological system
that may lead to systemic and multiple system impediments,
including reproductive efficiency.
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In this review we have highlighted literature indicating that
communication between the host immune system and the
microbial communities that reside in the vaginal cavity impact
reproductive health. Further elucidation of host-microbe inter-
actions within the vaginal cavity will enhance our understand-
ing of reproductive disease pathogenesis and potential causes for
impaired fertility. Overall, constant and vigilant screening of the
human microbiomes will provide early biomarkers in patients
that are deviating from a “normal” state prior to becoming clin-
ical symptomatic. More importantly understanding what is and
how to achieve the “perfect” balance of the human microbiomes
will provide the best medical weapon for individualized per-
sonnel medicine for prophylactic treatment of many pathogenic
conditions.
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